Skip to content

Prostate cancer under 50

How often it happens, family and genes, whether it is more aggressive and why I start PSA testing at 40.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 17, 2026
Book a consultation
Drawing of the prostate seen from above with a tumor and, beside it, an hourglass with almost all the sand still at the top, like a disease that appears early
On this page

Quick answer

Prostate cancer is most common after 65, but it also appears before 50. Without other risk factors, the European guideline considers the risk of a significant cancer at that age to be low.1 Even so, in the United States more than 10% of new diagnoses are in men aged 55 or younger.2 The risk is higher with a father or brother who had the disease, with some inherited mutations, such as in the BRCA2 gene, and in Black men.3,7 A PSA measured between 40 and 50 helps predict the risk over the following decades.4,5 In my practice, I recommend starting PSA testing at 40.

How often it appears before 50

Prostate cancer is usually thought of as a disease of older men. Yet in the United States, more than 10% of new diagnoses are in men aged 55 or younger.2

That share grew as PSA testing spread. In an American database of 318,774 men, the proportion of diagnoses at 55 or younger rose from 2.3% in 1988 to 1991 to 9% in 2000 to 2003.6

More recent data carry a warning. Between 2014 and 2021, cases rose again in the United States. In men younger than 55, the increase was confined to cancer that had already spread far from the prostate, which grew by 2.6% a year over the last decade of data.7

For a man with no other risk factors, the European guideline considers the risk of significant cancer before 50 to be low and advises starting PSA testing at that age.1 The starting age for each group is in when to start PSA testing.

Family history and genes

Family history weighs more when the cancer appears early. In a large American database cited by the European guideline, a family history multiplied the risk of prostate cancer overall by 2.3 and the risk of early-onset cancer by 3.9.3 The guideline calls prostate cancer hereditary when there are 3 or more cases in the family, cases in 3 successive generations, or 2 or more cases diagnosed before 55.3

A review of prostate cancer in young men describes a strong genetic component in this group.2 These are three of the genes the European guideline lists:3

GeneProstate cancer riskWhat else is known
BRCA22.5 to 4.6 times higher3At 55 or younger, risk 8 to 23 times higher. About 2% of men with early-onset cancer carry the mutation3
HOXB133.4 to 7.9 times higher3The G84E mutation was found in 3.1% of men with early-onset familial cancer and in 0.6% of late-onset cases with no family history8
Lynch syndrome genes3.7 times higher3Higher risk in MSH2 mutation carriers3

In a British study of BRCA2 mutation carriers, the chance of prostate cancer reached 27% by age 75. Gleason 7 or higher tumors were more frequent, and the risk of dying of the disease was higher than in the general population.9 For these men, the European guideline advises starting PSA testing at 40.1 The other genes and factors are in causes and risk factors.

When to consider genetic testing

The European guideline sets out genetic testing for inherited mutations this way:1

  • Offer testing to men with a known high-risk mutation in the family or several types of cancer on the same side of the family.
  • Recommend testing when several relatives had prostate cancer before 60, or when a relative died of it before 60.
  • Offer testing when analysis of the tumor itself found a BRCA mutation.

Genetic counseling comes before the test.1 When there is a family history, I ask who had the disease, at what age and whether there were other cancers, such as breast or ovarian cancer.

Black men

In the United States, Black men have 67% more prostate cancer cases than white men and twice the mortality from the disease.7 The European guideline advises starting PSA testing at 45 for men of African descent, the same age recommended for men with a relative diagnosed before 60.1

Is the tumor more aggressive in young men?

There is no single answer, and the studies look at different groups.

In the American database of 318,774 men, younger men had fewer high-grade tumors, although cancer confined to the prostate was also less frequent among them. As a group, they had better overall survival at 10 years and the same cancer-specific survival as older men. Among high-grade, advanced tumors, however, men aged 35 to 44 had the highest risk of dying of the cancer.6

The review of young men reached a similar picture. Most have low-risk disease, but with a high-grade, advanced tumor, a young man is more likely to die of it than an older man.2

In men aged 15 to 40, prostate cancer is rare. In the United States, they were more than 6 times as likely as older men to have spread disease at diagnosis.10

Age alone does not decide the treatment. Management is based on the risk group of each tumor, built from the PSA, the rectal exam and the biopsy report.11 How to read the report is in Gleason, ISUP and the biopsy report.

What a PSA at 40 to 50 predicts

In the Swedish city of Malmö, 21,277 men gave blood samples in the 1970s and 1980s, in a population where PSA testing was barely used. Years later, researchers measured PSA in the stored samples and compared it with what happened over the following decades.4,5

PSA measuredWhat happened later
Above the median, 0.63 ng/mL, at 44 to 5081% of advanced cancers, diagnosed up to 30 years later4
1.6 ng/mL or more, at 45 to 49These 10% of men accounted for 44% of prostate cancer deaths5
Below the median, 0.68 ng/mL, at 45 to 4915-year risk of metastasis of 0.09%. The authors could not rule out a risk at 25 to 30 years5

A single test at this stage separates a small group with higher risk decades later from a large group with low risk.4,5 The European guideline uses this logic: with a PSA above 1 ng/mL at 40, it suggests retesting every 2 years; for men not at increased risk, the next test can wait up to 8 years.1 In my practice, when the PSA is normal, I repeat it once a year. Expected values at each age are in PSA by age.

Symptoms

Localized prostate cancer usually causes no symptoms. They tend to appear when the disease is more advanced.1 A 42-year-old man who feels fine can have a tumor, which is why testing without complaints makes sense. A weak stream, frequent urination or blood in the urine have many causes and deserve evaluation at any age.

Treatment with decades ahead

A man diagnosed at 45 has many decades ahead of him. That cuts both ways: the tumor has more time to progress, and the side effects of treatment stay with him longer.2

For low risk, the European guideline recommends active surveillance, with regular tests. In other cases, surgery and radiotherapy are discussed along with the side effects of each.11 The comparison is in surgery or radiotherapy.

The choice takes continence and erections into account and is made case by case, with the patient. In a review of studies on robotic prostatectomy, age was among the factors that most affected urine leakage after surgery. In the pooled analysis, robotic surgery had better continence recovery at 12 months than open and laparoscopic surgery.12 These numbers describe groups of patients and do not predict any one person's result. I explain recovery in continence after prostatectomy and erections and ejaculation after prostatectomy.

How I approach it

I follow the guidelines, and the European one is the one I respect most. Even so, I recommend starting PSA testing at 40 for every man. I have seen, in real life, many patients between 40 and 45 with high-risk prostate cancer.

Before the test, I ask for at least 3 days of "rest" for the prostate: no ejaculation, no cycling and no rectal exam. If the PSA is normal, I repeat it once a year. If it is abnormal, I go straight to a prostate MRI, without repeating the PSA first. Free PSA and PSA density are not part of my routine.

When there is a family history, I ask who had the disease, at what age and whether there were other cancers, such as breast or ovarian cancer. With PI-RADS 3 or higher, I always recommend a biopsy, which I perform transperineally and always with sedation.

When surgery is the recommended treatment, I perform robotic radical prostatectomy. I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic, and in my practice functional recovery is better with the robotic approach. The first consultation can be at my office in Vila Mariana or online, in English.

When to see a urologist

  • From age 40, even without symptoms or a family history
  • If your father, a brother or other relatives had prostate cancer, especially before 60
  • If someone in your family carries a BRCA2 or other high-risk mutation, or there are several cases of breast, ovarian or prostate cancer on the same side of the family
  • If your PSA is abnormal, at any age
  • If you have urinary symptoms or blood in the urine

Frequently asked questions

Can a 40-year-old man get prostate cancer?

Yes. It is less common than after 65, but it happens. In the United States, more than 10% of new diagnoses are in men aged 55 or younger.2 Without other risk factors, the European guideline considers the risk of significant cancer before 50 to be low.1 In my practice, I have seen many patients between 40 and 45 with high-risk prostate cancer.

Why do you recommend starting PSA testing at 40?

The European guideline advises starting at 50, at 45 with a family history or African ancestry, and at 40 for BRCA2 carriers.1 I follow the guidelines, but I recommend 40 for every man because I have seen, in real life, many patients between 40 and 45 with high-risk cancer. A PSA measured at that stage also helps predict the risk over the following decades.4,5 Men with a BRCA2 mutation or many cases in the family also start at 40 with me, with a PSA once a year.

Is prostate cancer more aggressive in young men?

The evidence is mixed. Younger men generally have fewer high-grade tumors, but when the tumor is high grade and advanced, they are more likely to die of it than older men.2,6 Treatment is guided by the risk group of each tumor.11

Is prostate cancer before 50 hereditary?

Family history matters more when the cancer appears early. It multiplied the risk of early-onset prostate cancer by about 3.9.3 Among other situations, the European guideline calls it hereditary when 2 or more family members were diagnosed before 55.3

Who should have genetic testing?

The European guideline advises offering testing to men with a known high-risk mutation in the family or several types of cancer on the same side of the family, and recommends it when several relatives had prostate cancer before 60 or a relative died of it before 60. Genetic counseling comes before the test.1

What does a PSA at 40 or 50 say about the future?

In a Swedish study, a single PSA measured at or before 50 predicted advanced cancer diagnosed up to 30 years later.4 Between 45 and 49, the 10% of men with the highest PSA, 1.6 ng/mL or more, accounted for 44% of deaths from the disease.5

Does prostate cancer cause symptoms in young men?

Usually not. Localized cancer rarely causes symptoms, which tend to appear later.1 Feeling well does not rule it out.

How is prostate cancer treated in men under 50?

It depends on the risk group. For low risk, the European guideline recommends active surveillance; in other cases, surgery and radiotherapy are discussed along with the side effects of each.11 Because a young man will live with the result for decades, the choice takes continence and erections into account and is made case by case.2,12

Who treats prostate cancer in young men in São Paulo?

I treat men with prostate cancer in São Paulo, including men under 50. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. I recommend starting PSA testing at 40, and when the PSA is abnormal I go straight to an MRI. My office is in Vila Mariana, and the first consultation can be in person or online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. EAU
  2. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11(6):317-323. PubMed
  3. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. Epidemiology and aetiology chapter. EAU
  4. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117(6):1210-1219. PubMed
  5. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023. PubMed
  6. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009;115(13):2863-2871. PubMed
  7. Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025;75(6):485-497. PubMed
  8. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141-149. PubMed
  9. Nyberg T, Frost D, Barrowdale D, et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol. 2020;77(1):24-35. PubMed
  10. Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2020;126(1):46-57. PubMed
  11. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148-163. PubMed
  12. Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):405-417. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides